Omeros (OMER) Total Liabilities (2010 - 2026)
Omeros (OMER) posted Total Liabilities of $286.2 million for Q1 2026, down 12.12% sequentially from $325.6 million in Q4 2025, and up 21.69% YoY from $235.2 million in Q1 2025.
Omeros (OMER) Total Liabilities (2010 - 2026) Analysis & Trends
Omeros has reported Total Liabilities for 17 years, with the latest figure at $286.2 million in Q1 2026.
- Quarterly Total Liabilities rose 21.69% year-over-year to $286.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $286.2 million (up 21.69% YoY) and the FY2025 annual result came in at $325.6 million, up 17.52% from the prior year.
- Total Liabilities eased to $286.2 million in Q1 2026 per OMER's latest filing, from $325.6 million in the prior quarter.
- Over five years, Total Liabilities peaked at $591.0 million in Q4 2022 and troughed at $185.7 million in Q3 2025.
- A 5-year average of $372.9 million and a median of $356.3 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 270.7% in 2022, then sank 46.25% in 2025.
- Over 5 years, Total Liabilities stood at $591.0 million in 2022, then slumped by 35.99% to $378.3 million in 2023, then fell by 26.75% to $277.1 million in 2024, then grew by 17.52% to $325.6 million in 2025, then slipped by 12.12% to $286.2 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $286.2 million, $325.6 million, and $185.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 286.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 286.83 Mn |
| Mar 31, 2026 | 286.17 Mn |
| Dec 31, 2025 | 325.63 Mn |
| Sep 30, 2025 | 185.71 Mn |
| Jun 30, 2025 | 200.57 Mn |
| Mar 31, 2025 | 235.16 Mn |
| Dec 31, 2024 | 277.08 Mn |
| Sep 30, 2024 | 313.34 Mn |
| Jun 30, 2024 | 356.31 Mn |
| Mar 31, 2024 | 437.49 Mn |
| Dec 31, 2023 | 378.27 Mn |
| Sep 30, 2023 | 493.07 Mn |
| Jun 30, 2023 | 527.42 Mn |
| Mar 31, 2023 | 560.13 Mn |
| Dec 31, 2022 | 590.97 Mn |
| Sep 30, 2022 | 457.55 Mn |
| Jun 30, 2022 | 345.64 Mn |
| Mar 31, 2022 | 369.26 Mn |
| Dec 31, 2021 | 419.27 Mn |
| Sep 30, 2021 | 123.43 Mn |